Table 3.
Patient‐reported outcome measures for patients with PsO and no diagnosis of PsA, stratified by PEST score
| Characteristic | PEST ≥3 n = 112 | PEST <3 n = 792 | P value |
|---|---|---|---|
| Patient pain (VAS 0–100), mean (SD) | 28.3 (30.6) | 21.3 (28.7) | 0.015 |
| Patient‐reported fatigue (VAS 0–100), mean (SD) | 41.7 (27.8) | 25.0 (26.8) | <0.001 |
| EQ VAS (0–100), mean (SD) | 67.0 (22.9) | 76.4 (21.2) | <0.001 |
| DLQI (0–30), mean (SD) | 8.1 (6.5) | 6.2 (5.9) | 0.002 |
| DLQI (‘effect on life’), n (%) | n = 112 | n = 792 | |
| None (0–1) | 21 (18.8) | 196 (24.7) | 0.035 |
| Small (2–5) | 27 (24.1) | 258 (32.6) | |
| Moderate (6–10) | 27 (24.1) | 160 (20.2) | |
| Very large (11–20) | 33 (29.5) | 145 (18.3) | |
| Extremely large (21–30) | 4 (3.6) | 33 (4.2) | |
| WPAI summary scores | |||
| Currently employed, n (%) | 60 (53.6) | 561 (71.0) | |
| WPAI domains, mean (SD) [n] | |||
| % Work time missed | 2.9 (7.9) [n = 57] | 2.6 (10.7) [n = 505] | 0.795 |
| % Impairment while working | 13.3 (21.9) [n = 57] | 10.2 (18.7) [n = 502] | 0.238 |
| % Overall work impairment | 14.8 (23.5) [n = 57] | 11.5 (20.2) [n = 502] | 0.251 |
| % Activity impairment | 24.0 (28.6) [n = 111] | 15.0 (23.6) [n = 787] | <0.001 |
DLQI, Dermatology Life Quality Index; EQ VAS, EuroQol visual analogue scale; PEST, Psoriasis Epidemiology Screening Tool; PsA, psoriatic arthritis; PsO, psoriasis; VAS, visual analog scale; WPAI, Work Productivity and Activity Impairment.